IMS Signs Agreement to Divest SDI Medical and Promotional Audits
DANBURY, CT, January 17, 2012 – IMS Health announced today that it has entered into an agreement with inVentiv Health to divest certain promotional and medical market research products of SDI Health, a Pennsylvania-based healthcare market insights and analytics firm. IMS completed the purchase of SDI on October 31, 2011, and as part of that transaction agreed to divest 11 SDI data products to satisfy U.S. Federal Trade Commission regulatory requirements. The divested products represent less than $15 million or approximately 10 percent of SDI’s 2011 revenue.
IMS will continue to support and market its existing medical and promotional services worldwide, including the company’s National Disease and Therapeutic Index (NDTI) and Integrated Promotional Services (IPS) offerings in the U.S.
With the acquisition of SDI, IMS continues to build more innovative and comprehensive capabilities in the patient and payer spaces, consistent with the company’s strategy to significantly expand its business in healthcare information, technology and services.
About IMS Health
IMS Health is the leading provider of information, services and technology for the healthcare industry around the world. The company draws on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and consulting platforms to help clients better understand the performance and value of medicines. With a presence in 100+ countries and more than 55 years of industry experience, IMS serves leading decision makers in healthcare, including pharmaceutical manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. Additional information is available at http://www.imshealth.com.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.